199 related articles for article (PubMed ID: 30557675)
1. The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care.
Ning MS; Gomez DR; Shah AK; Kim CR; Palmer MB; Thaker NG; Grosshans DR; Liao Z; Chapman BV; Brooks ED; Tang C; Rosenthal DI; Garden AS; Frank SJ; Gunn GB
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):724-733. PubMed ID: 30557675
[TBL] [Abstract][Full Text] [Related]
2. Insurance Approval for Proton Beam Therapy and its Impact on Delays in Treatment.
Gupta A; Khan AJ; Goyal S; Millevoi R; Elsebai N; Jabbour SK; Yue NJ; Haffty BG; Parikh RR
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):714-723. PubMed ID: 30557673
[TBL] [Abstract][Full Text] [Related]
3. Young Adult Populations Face Yet Another Barrier to Care With Insurers: Limited Access to Proton Therapy.
Bishop AJ; Livingston JA; Ning MS; Valdez ID; Wages CA; McAleer MF; Paulino AC; Grosshans DR; Woodhouse KD; Tao R; Roth ME; Gunn GB; McGovern SL
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1496-1504. PubMed ID: 33677051
[TBL] [Abstract][Full Text] [Related]
4. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.
Do A; Mittal Y; Liapakis A; Cohen E; Chau H; Bertuccio C; Sapir D; Wright J; Eggers C; Drozd K; Ciarleglio M; Deng Y; Lim JK
PLoS One; 2015; 10(8):e0135645. PubMed ID: 26312999
[TBL] [Abstract][Full Text] [Related]
5. Insurance Authorization and Access to Proton Therapy for Patients With Head and Neck Cancers.
McDonald MW; Bates JE; McCall NS; Goyal S; Liu Y; Rudra S; Remick JS; Tian S; El-Deiry MW; Saba NF; Stokes WA; Swinney E
Int J Radiat Oncol Biol Phys; 2023 Jun; 116(2):404-412. PubMed ID: 36889515
[TBL] [Abstract][Full Text] [Related]
6. Three-Year Results of a Prospective Statewide Insurance Coverage Pilot for Proton Therapy: Stakeholder Collaboration Improves Patient Access to Care.
Ning MS; Palmer MB; Shah AK; Chambers LC; Garlock LB; Melson BB; Frank SJ
JCO Oncol Pract; 2020 Sep; 16(9):e966-e976. PubMed ID: 32302271
[TBL] [Abstract][Full Text] [Related]
7. The impact of prior authorization review on orthopaedic subspecialty care: a prospective multicenter analysis.
Jarrett CD; Dawes A; Abdelshahed M; Cil A; Denard P; Port J; Weinstein D; Wright MA; Bushnell BD
J Shoulder Elbow Surg; 2024 Jun; 33(6):e336-e342. PubMed ID: 37993089
[TBL] [Abstract][Full Text] [Related]
8. Principles and reality of proton therapy treatment allocation.
Bekelman JE; Asch DA; Tochner Z; Friedberg J; Vaughn DJ; Rash E; Raksowski K; Hahn SM
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):499-508. PubMed ID: 24798985
[TBL] [Abstract][Full Text] [Related]
9. Insurance coverage decisions for pediatric proton therapy.
Ojerholm E; Hill-Kayser CE
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28782877
[TBL] [Abstract][Full Text] [Related]
10. Proton radiotherapy and treatment delay in head and neck squamous cell carcinoma.
Jin MC; Harris JP; Sabolch AN; Gensheimer M; Le QT; Beadle BM; Pollom EL
Laryngoscope; 2020 Nov; 130(11):E598-E604. PubMed ID: 31837165
[TBL] [Abstract][Full Text] [Related]
11. Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations.
Dudiak GJ; Popyack J; Grimm C; Tyson S; Solic J; Ishmael FT
Allergy Asthma Proc; 2021 Jan; 42(1):65-71. PubMed ID: 33404389
[No Abstract] [Full Text] [Related]
12. Socioeconomic factors affect the selection of proton radiation therapy for children.
Shen CJ; Hu C; Ladra MM; Narang AK; Pollack CE; Terezakis SA
Cancer; 2017 Oct; 123(20):4048-4056. PubMed ID: 28654202
[TBL] [Abstract][Full Text] [Related]
13. Insurance Denials in Reduction Mammaplasty: How Can We Serve Our Patients Better?
Boukovalas S; Boson AL; Padilla PL; Sljivich M; Tran JP; Spratt H; Phillips LG
Plast Reconstr Surg; 2020 Aug; 146(2):127e-136e. PubMed ID: 32740569
[TBL] [Abstract][Full Text] [Related]
14. Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease.
Shah NB; Zuckerman AD; Hosteng KR; Fann J; DeClercq J; Choi L; Cherry L; Schwartz DA; Horst S
Dig Dis Sci; 2023 Dec; 68(12):4331-4338. PubMed ID: 37725192
[TBL] [Abstract][Full Text] [Related]
15. Proton therapy expansion under current United States reimbursement models.
Kerstiens J; Johnstone PA
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):235-40. PubMed ID: 24685152
[TBL] [Abstract][Full Text] [Related]
16. Insurance Coverage for Adjuvant Proton Therapy in the Definitive Treatment of Breast Cancer.
Mendenhall WM; Smith S; Morris CG; Bradley JA; Mailhot Vega RB; McIntyre K; Klein SL; Mendenhall NP
Int J Part Ther; 2019; 6(2):26-30. PubMed ID: 31998818
[TBL] [Abstract][Full Text] [Related]
17. Insurance Coverage of Biologics for Moderate-to-Severe Psoriasis: A Retrospective, Observational 5-Year Chart Review.
Abdelnabi M; Patel A; Rengifo-Pardo M; Ehrlich A
Am J Clin Dermatol; 2016 Aug; 17(4):421-4. PubMed ID: 27283586
[TBL] [Abstract][Full Text] [Related]
18. Strategic Operational Redesign for Successfully Navigating Prior Authorization Barriers at a Large-Volume Proton Therapy Center.
Brooks ED; Ning MS; Palmer MB; Gunn GB; Frank SJ; Shah AK
JCO Oncol Pract; 2020 Oct; 16(10):e1067-e1077. PubMed ID: 32639929
[TBL] [Abstract][Full Text] [Related]
19. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
Hess GP; Natarajan P; Faridi KF; Fievitz A; Valsdottir L; Yeh RW
Circulation; 2017 Dec; 136(23):2210-2219. PubMed ID: 29084735
[TBL] [Abstract][Full Text] [Related]
20. Ethical Allocation of Proton Therapy and the Insurance Review Process.
Grzywacz V; Quinn TJ; Wilson T; Reitemeier P; Navin M; Hamstra D; Anderson J; Chinnaiyan P; Stevens C; Kabolizadeh P
Pract Radiat Oncol; 2021; 11(5):e449-e458. PubMed ID: 33548544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
